Literature DB >> 56215

Low dose bleomycin and methotrexate in cervical cancer.

J F Conroy, G C Lewis, L W Brady, I Brodsky, S B Kahn, D Ross, R Nuss.   

Abstract

Twenty patients with recurrent and disseminated carcinoma of the cervix were treated with Bleomycin, 10 mg/m2 weekly and Methotrexate, 10 mg/m2 every fourth day. Twelve of the 20 (60%) had a greater than 50% shrinking of measured tumor masses lasting a median remission time of 7.5 months. The data suggest that combination protracted chemotherapy with these drugs of metastatic cervical cancer might improve the outlook of patients with this condition.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 56215     DOI: 10.1002/1097-0142(197602)37:2<660::aid-cncr2820370208>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  "Unresectable" vulval cancers: is neoadjuvant chemotherapy the way forward?

Authors:  Kathryn Graham; Kevin Burton
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Chemotherapy for advanced recurrent carcinoma of the cervix. A report on the treatment of 22 patients.

Authors:  K von Maillot; I M Ranger
Journal:  Arch Gynecol       Date:  1982
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.